Deciphera Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 4, 2021
- Wall Street ends sharply higher after Powell comments
- Salesforce (CRM) shares slide despite topping earnings, revenue expectations
- Fed's Powell: Rate hikes to slow, but adjustment just beginning
- Snowflake shares plunge 13% despite Q3 beat
- Market turmoil and economic decline, before recovery in 2023, says JPM's Kolanovic
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its first quarter 2021 financial results on Tuesday, May 4, 2021.
In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 4:30 PM ET on Tuesday, May 4, 2021, to discuss the Company’s financial results and provide a corporate update.
The conference call may be accessed by dialing (866) 930-5479 (domestic) or (409) 216-0603 (international) and referring to conference ID 5470938. A webcast of the conference call will be available in the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/news-events/events-presentations. The archived webcast will be available on the Company's website approximately two hours after the conference call and will be available for 30 days following the call.
About Deciphera Pharmaceuticals
Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumors. For more information, visit https://www.deciphera.com/ or follow us on LinkedIn and Twitter (@Deciphera).
Source: Deciphera Pharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Salesforce (CRM) Tops Q3 EPS by 18c, Offers Guidance
- Navidea Biopharmaceuticals Files Appeal in CRG Case
- 8x8, Inc. (EGHT) Terminates Employment Relationship With CEO Dave Sipes
Create E-mail Alert Related CategoriesBusiness Wire, Press Releases
Related EntitiesTwitter, Earnings, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!